You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.
Are you sure you want to leave?
Cancel
Vifor Pharma made an impact at ERA–EDTA 2019
From 13 June to 16 June 2019, Vifor Pharma was at the 56th ERA–EDTA Congress in Budapest, Hungary. We hosted a disease state education booth and sponsored an educational symposium with the aim of enhancing awareness of secondary hyperparathyroidism (SHPT) and the limitations of current treatments.
Our booth sparked intense debates
Physicians who visited our booth, which we set up in one of the e-campus learning stations, were able to:
- See how up-to-date their SHPT knowledge was by taking the SHPT Challenge (an interactive challenge that tests physicians’ understanding of SHPT and its treatment)
- Watch our animation on the unmet needs of SHPT treatment (which you can view right now on our Watch page)
- Take hard copies of two of our leaflets: ‘Unmet Needs in SHPT Treatment’ and ‘KDIGO CKD–MBD Quick Reference Guide’ (which you can find on our Download page)
The booth was a success, attracting lots of attention and stimulating passionate discussions.
Our educational symposium was a hit
Entitled ‘Navigating CKD–MBD in 2019: expert perspectives’, the symposium was chaired by Professor Jordi Bover* and attracted a very attentive audience.
Consisting of two presentations, the symposium began with an introduction from Professor Bover, who outlined SHPT and its pathogenesis. This was followed by the first presentation, delivered by Professor Markus Ketteler,† who explored the current concepts and controversies inherent to the management of SHPT in both predialysis and dialysis patients.
The second presentation was given by Associate Professor Marc Vervloet,‡ who considered the challenges associated with the management of hyperphosphataemia, including appropriate phosphate targets and current and future strategies that may help patients achieve them.
Watch the highlights now
If you missed the symposium, you can watch the highlights below.
Footnotes
*Clinical Professor of Nephrology; Nephrology Department, Fundació Puigvert, Universitat Autònoma de Barcelona; Catalonia, Spain.
†Head of General Internal Medicine and Nephrology; Robert-Bosch-Krankenhaus; Stuttgart, Germany.
‡Associate Professor; Department of Nephrology, VU University Medical Center; Amsterdam, the Netherlands
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care. For more information about Vifor Pharma, please visit www.viforpharma.com
This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site's accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.
© 2021 Vifor Fresenius Medical Care Renal Pharma
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology …
Read More
